Weuphoria Special Precautions

Do not vaccinate via intravenous route or by gluteal intramuscular injection, and ensure the syringe needle is not puncturing blood vessel during inoculation.
Check if the package, container, label, appearance and expiration date of the vaccines are in compliance with corresponding requirements before administration. Do not use the vaccine in case that any crack is observed in the container, loosened stopper, detached label, foreign particle(s) or discoloring inside the container, etc.
Use immediately after unsealing. A single human dose shall be used up each time according to prescribing information.
The vaccination should be postponed in case of fever, acute disease, and acute attack of chronic disease.
Appropriate monitoring and medical care rescue measures should be readily available in case of occurrence of rare hypersensitivity reactions during vaccination. If allergic reactions occur after vaccination, go to the vaccination site or hospital in time.
Cautions should be taken for vaccination in recipients with thrombocytopenia, any coagulopathy or those who are receiving anticoagulant treatment.
Given that no safety and immunogenicity data are available for PCV13-TT in immunocompromised individuals (e.g., malignancy or nephrotic syndrome), vaccination in this special group should be considered on an individual basis.
Under no circumstances shall the tetanus toxoid contained in the vaccine replace the routine immunization of tetanus vaccine or tetanus-containing vaccine.
This product cannot guarantee all recipients can be protected from any diseases caused by Streptococcus pneumoniae.
Use in Children: Preterm infants should be monitored for the potential risk of apnea during primary series. For preterm infants under hospitalization (gestational age ≤ 30 weeks at birth) vaccinated with PCV13-TT according to the recommended immunization schedule, at least 48 hours of monitoring should be considered. Given the benefit of vaccination in preterm infants, discontinued or deferred vaccination of the product is not recommended.
The use of PCV13-TT does not replace the use of 23-Valent Pneumococcal Polysaccharide Vaccines in children ≥ 24 moths of age with conditions such as sickle cell disease, asplenia, HIV infection, chronic illness, or those who are immunocompromised.